UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 607

Sortiert nach

Small cell lung cancer: Where do we go from here?

Cancer, 2015-03, Vol.121 (5), p.664-672

2015

Link zum Volltext

Verfügbarkeit prüfen

CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future

Frontiers in oncology, 2020-08, Vol.10, p.1387-1387

2020

Link zum Volltext

Verfügbarkeit prüfen

Small-cell lung cancer

Nature reviews. Disease primers, 2021-01, Vol.7 (1), p.3-3, Article 3

2021

Link zum Volltext

Verfügbarkeit prüfen

Lineage plasticity in cancer: a shared pathway of therapeutic resistance

Nature reviews. Clinical oncology, 2020-06, Vol.17 (6), p.360-371

2020

Link zum Volltext

Verfügbarkeit prüfen

Vismodegib

Clinical cancer research, 2012-06, Vol.18 (12), p.3218-3222

RUDIN, Charles M

2012

Link zum Volltext

Verfügbarkeit prüfen

NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination

Science (American Association for the Advancement of Science), 2018-12, Vol.362 (6421), p.1416-1422

2018

Link zum Volltext

Verfügbarkeit prüfen

Tarlatamab: New Star on the Horizon for Small-Cell Lung Cancer?

Journal of clinical oncology, 2023-06, Vol.41 (16), p.2877-2880

2023

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

Journal of clinical oncology, 2020-07, Vol.38 (21), p.2369-2379

2020

Link zum Volltext

Verfügbarkeit prüfen

Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial

The lancet oncology, 2016-12, Vol.17 (12), p.1653-1660

2016

Link zum Volltext

Verfügbarkeit prüfen

Targeted Therapies and Biomarkers in Small Cell Lung Cancer

Frontiers in oncology, 2020-05, Vol.10, p.741-741

2020

Link zum Volltext

Verfügbarkeit prüfen

Genomic Analysis of Smoothened Inhibitor Resistance in Basal Cell Carcinoma

Cancer cell, 2015-03, Vol.27 (3), p.327-341

2015

Link zum Volltext

Verfügbarkeit prüfen

Small cell lung cancer: will recent progress lead to improved outcomes?

Clinical cancer research, 2015-05, Vol.21 (10), p.2244-2255

2015

Link zum Volltext

Verfügbarkeit prüfen

Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.1784-1793

2019

Link zum Volltext

Verfügbarkeit prüfen

The future of epigenetic therapy in solid tumours--lessons from the past

Nature reviews. Clinical oncology, 2013-05, Vol.10 (5), p.256-266

2013

Link zum Volltext

Verfügbarkeit prüfen

Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline

Journal of clinical oncology, 2015-12, Vol.33 (34), p.4106-4111

2015

Link zum Volltext

Verfügbarkeit prüfen

A combinatorial strategy for treating KRAS-mutant lung cancer

Nature (London), 2016-06, Vol.534 (7609), p.647-651

2016

Link zum Volltext

Verfügbarkeit prüfen

Unravelling the biology of SCLC: implications for therapy

Nature reviews. Clinical oncology, 2017-09, Vol.14 (9), p.549-561

2017

Link zum Volltext

Verfügbarkeit prüfen

High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden

Clinical cancer research, 2019-08, Vol.25 (15), p.4712-4722

2019

Link zum Volltext

Verfügbarkeit prüfen

Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets

Clinical cancer research, 2016-07, Vol.22 (14), p.3618-3629

2016

Link zum Volltext

Verfügbarkeit prüfen

TMEM41B Is a Pan-flavivirus Host Factor

Cell, 2021-01, Vol.184 (1), p.133-148.e20

2021

Link zum Volltext

Verfügbarkeit prüfen

Molecular Characterization of Acquired Resistance to the BRAF Inhibitor Dabrafenib in a Patient with BRAF-Mutant Non–Small-Cell Lung Cancer

Journal of thoracic oncology, 2013-05, Vol.8 (5), p.e41-e42

2013

Link zum Volltext

Verfügbarkeit prüfen

Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR -Mutant Lung Cancers

Clinical cancer research, 2019-02, Vol.25 (3), p.1063-1069

2019

Link zum Volltext

Verfügbarkeit prüfen

Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer

Oncogene, 2019-01, Vol.38 (5), p.656-670

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study

Clinical cancer research, 2019-12, Vol.25 (23), p.6958-6966

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 607

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(577)
Mit Volltextzugriff
(557)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(605)
Japanisch
(86)
Russisch
(1)
Serbian
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(322)
Life Sciences & Biomedicine
(304)
Humans
(294)
Oncology
(230)
Female
(118)
Male
(114)
Animals
(111)
Lung Neoplasms - Drug Therapy
(106)
Lung Neoplasms - Genetics
(94)
Middle Aged
(94)
Lung Neoplasms - Pathology
(92)
Aged
(88)
Mice
(87)
Tumors
(73)
Lung Cancer
(72)
Adult
(67)
Mutation
(67)
Biological And Medical Sciences
(63)
Medical Sciences
(54)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(51)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Small cell lung cancer: Where do we go from here?

CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future

Small-cell lung cancer

Lineage plasticity in cancer: a shared pathway of therapeutic resistance

Vismodegib

NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination

Tarlatamab: New Star on the Horizon for Small-Cell Lung Cancer?

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial

Targeted Therapies and Biomarkers in Small Cell Lung Cancer

Genomic Analysis of Smoothened Inhibitor Resistance in Basal Cell Carcinoma

Small cell lung cancer: will recent progress lead to improved outcomes?

Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes

The future of epigenetic therapy in solid tumours--lessons from the past

Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline

A combinatorial strategy for treating KRAS-mutant lung cancer

Unravelling the biology of SCLC: implications for therapy

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden

Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets

TMEM41B Is a Pan-flavivirus Host Factor

Molecular Characterization of Acquired Resistance to the BRAF Inhibitor Dabrafenib in a Patient with BRAF-Mutant Non–Small-Cell Lung Cancer

Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR -Mutant Lung Cancers

Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer

Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study

Suchergebnisse filtern